Cannabix Technologies Inc. (OTC: BLOZF) Is Developing the Medicinal-Plant Detection Solution Law Enforcement Has Been Waiting For
Remember medicinal-plant stocks in 2018 when Canada legalized? Yes, one of the most legendary bull markets of all time. Well, buckle up, because we may be about to enter an even more savage medicinal-plant bull market as the USA is on the fence about a nation wide legalization, and even Germany just pulled the trigger. With the size of the US & German market making Canada’s look like a corner store, this potential upcoming medicinal-plant bull market could turn Garbage men to quants overnight.
We aren't chasing the next big grower, we are eyeing the inevitable, the infrastructure play. And that’s where Cannabix Technologies Inc (OTC: BLOZF) comes in.
The Problem Nobody’s Talking About
Here’s the deal - as medicinal-plant continues to be legalized across more and more states, how will law enforcement accurately test for impairment? They need to be able to detect for recent use, meaning the time window, typically 1-3 hours after lighting up or taking an edible. Blood tests can detect for many days after use. Urine tests show usage from weeks ago. Cops, employers, and insurance companies need answers about recent consumption. Drug testing methods like urine, hair and spit don’t provide fair and relevant results.
Currently, 18 states plus Washington D.C. have full legalization, with another 18 states allowing just medical use. Two-thirds of Americans support legalization, and the federal government is considering moving the medicinal-plant from Schedule I to Schedule III. The writing’s on the wall is it's going mainstream.
But here’s what most investors don’t realize: every single state that fully legalizes the medicinal-plant creates a massive new market for testing technology. Law enforcement needs it. Employers demand it. Insurance companies require it. And right now, there’s no good solution.
Why Cannabix Technologies Inc.'s Testing Changes Everything
Cannabix Technologies Inc. (OTC: BLOZF) has developed a Breath Test called MBT - and it’s exactly what it sounds like. Think breathalyzer for testing medicinal-plant impairment, but way more sophisticated.
Their M. Breath Test (MBT) technology works to collect and detect medicinal-plant use within 1-3 hours after smoking or edibles, which is the actual impairment window. The handheld device collects a standardized breath sample in less than 2 minutes, requires no medical training to operate, the sample is then analyzed using gold standard mass spectrometry, the kind of real-time results that law enforcement and employers actually need.
The company has partnered with Omega Laboratories for analysis, creating a complete testing ecosystem. It’s non-invasive, fast turnaround, and addresses the exact problem that’s been holding back broader medicinal-plant acceptance in workplace and public safety contexts.
This isn’t some pie-in-the-sky technology either. The testing technology is real, it’s been developed, and they’re positioning for commercial rollout as the regulatory environment catches up.
Why the Market Opportunity is Massive
Think about the scale here. Every police department in medicinal-plant legal states needs this technology. Every major employer in legal jurisdictions wants workplace testing capabilities. Insurance companies are demanding better impairment detection before they’ll provide coverage.
The federal recommendation to move the medicinal-plant to Schedule III would make research easier and reduce legal penalties while maintaining federal oversight. That’s actually perfect for a testing company - it legitimizes the market while creating regulatory demand for their solutions.
Medicinal-plant related hospitalizations are increasing as usage grows, creating additional demand from healthcare providers who need to understand patient impairment levels. The medicinal-plant Breath Detection market is set to explode as legalization expands and institutions demand practical testing solutions.
The Investment Thesis
Cannabix Technologies Inc. Stock (OTC: $BLOZF) is trading around attractive levels for a company positioned at the center of a massive infrastructure buildout. They’re not competing with dozens of growers or fighting for dispensary licenses. They’re solving a fundamental problem that every legal market needs addressed.
The company has been investing heavily in R&D, with operating expenses growing from CAD 2.28 million in 2022 to CAD 5.95 million in 2025. That’s not just burning cash - that’s building the technology infrastructure for a multi-billion dollar market opportunity.
Yes, they’re pre-revenue right now, which means higher risk. But it also means you’re getting in before the commercial rollout begins. When law enforcement agencies and major employers start adopting their Testing Technology, the revenue ramp could be dramatic.
The company trades on multiple exchanges (OTC: BLOZF, CSE: BLO, Frankfurt: 8CT), providing liquidity and legitimacy that many cannabis plays lack.
Bottom Line
Ticker: $BLOZF (OTC) / $BLO (CSE)
Cannabix Technologies Inc. offers leveraged exposure to the medicinal-plant legalization infrastructure buildout. Their Breath Detection technology addresses a critical market need that’s only growing as more states legalize cannabis.
This isn’t a safe dividend play - it’s a high-risk, high-reward bet on testing technology becoming essential infrastructure. If they execute, the upside could be massive. If they don’t, you could lose everything.
Do your own research, don’t bet the farm, but if you’re looking for a different angle on the medicinal-plant story, this might be worth a look.
If you are interested in learning more - $BLOZF $BLO.CN was just featured on Zero Hedge. Click the link here to read it: Zero Hedge Article
This communication contains forward-looking statements that involve significant risks and uncertainties. All statements other than those of historical fact, including statements regarding the company’s strategies, plans, objectives, future financial position, projected market growth, anticipated adoption of cannabis testing technology, potential regulatory changes, and the impact of legalization trends and government policies, are forward-looking statements. These statements are based on current expectations and assumptions that are subject to known and unknown risks, uncertainties, and other factors that may cause actual results or performance to differ materially from those expressed or implied. Such risks include but are not limited to regulatory approvals, commercialization of new technology, product performance, market adoption, research and development outcomes, competitive pressures, general economic conditions, and the company’s ability to raise additional capital when required. The company undertakes no obligation to update or revise any forward-looking statements except as required by applicable securities laws. Investors are cautioned not to place undue reliance on these statements, which speak only as of the date hereof. The potential for increased cannabis legalization, market expansion, and the company’s ability to benefit from these developments remain speculative and subject to material uncertainty. This material is a paid advertisement and not a recommendation to buy or sell any securities. VHLA Media Inc. and its owners, managers, employees, and affiliates have been paid a total of one hundred thousand Canadian dollars (CAD $100,000) plus applicable taxes by Cannabix Technologies Inc. for an ongoing marketing campaign that includes this communication and related promotional activities. VHLA Media Inc., its affiliates, and principals do not currently own any securities of Cannabix Technologies Inc. but may buy or sell such securities at any given moment without further notice. This compensation creates a conflict of interest, and readers should assume that VHLA Media Inc. is biased in its statements about the company. This communication is for informational and entertainment purposes only and should not be used as a basis for any investment decision. VHLA Media Inc. and its principals are not registered investment advisors, broker-dealers, or licensed financial professionals in any jurisdiction, and nothing in this communication should be construed as personalized investment advice. Investors are strongly encouraged to perform their own independent due diligence and consult a licensed financial advisor or registered securities professional before making any investment decisions. Investing in securities, particularly microcap and small-cap issuers, involves a high degree of risk and volatility. Past performance is not indicative of future results, and no representation or warranty is made regarding future performance or outcomes. This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction where such activity would be unlawful. Comparisons or references to other issuers are provided for illustrative purposes only and are not intended as investment recommendations.
.svg)
